Health Technology Eisai Co., Ltd. Business Summary
Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.
Financial Highlights
Mar 2022
JPY USD Revenue 756,226M 6,729.62M Gross Profit 569,791M 5,070.54M Operating income 59,623M 530.58M Income before tax 54,458M 484.61M Net income 47,954M 426.74M EBITDA 98,021M 872.28M Diluted EPS 167.24 1.48 Dividends Per Share 160 1.42 Total Assets 1,239.31B 10,210.62M Total liabilities 467,781M 3,854.01M Total equity 748,821M 6,169.48M Operating cash flow 117,590M 1,046.42M Currency in JPY Currency in USD
Historical Data Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Revenue
600,054M
642,834M
695,621M
645,942M
756,226M
Gross Profit
386,599M
446,436M
510,352M
465,186M
569,791M
Operating income
75,595M
99,921M
138,679M
56,543M
59,623M
Income before tax
76,803M
89,454M
128,063M
52,551M
54,458M
Net income
51,845M
63,386M
121,767M
42,119M
47,954M
EBITDA
101,778M
126,762M
172,379M
92,842M
98,021M
Diluted EPS
180.97
221.11
424.79
146.90
167.24
Dividends Per Share
150
150
160
160
160
Total Assets
1,049.03B
1,071.52B
1,062.14B
1,090.00B
1,239.31B
Total liabilities
434,934M
419,539M
359,509M
362,067M
467,781M
Total equity
593,582M
628,120M
678,127M
703,183M
748,821M
Operating cash flow
149,649M
103,714M
102,782M
73,853M
117,590M
Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Revenue
5,414.06M
5,796.79M
6,397.94M
6,090.49M
6,729.62M
Gross Profit
3,488.14M
4,025.76M
4,693.93M
4,386.17M
5,070.54M
Operating income
682.06M
901.04M
1,275.49M
533.13M
530.58M
Income before tax
692.96M
806.65M
1,177.85M
495.49M
484.61M
Net income
467.77M
571.58M
1,119.94M
397.13M
426.74M
EBITDA
918.30M
1,143.08M
1,585.44M
875.39M
872.28M
Diluted EPS
1.63
1.99
3.90
1.38
1.48
Dividends Per Share
1.35
1.35
1.47
1.50
1.42
Total Assets
9,863.94M
9,680.80M
9,838.72M
9,864.33M
10,210.62M
Total liabilities
4,089.64M
3,790.38M
3,330.17M
3,276.62M
3,854.01M
Total equity
5,581.39M
5,674.84M
6,281.57M
6,363.64M
6,169.48M
Operating cash flow
1,350.22M
935.24M
945.33M
696.34M
1,046.42M
Valuation Measures
Mar 2022
PER 33.89 ROA 4.11% ROE 6.60% Operating margin 7.88% Profit margin 6.34%
Key executives
Chief Executive Officer & Representative Director:
Haruo Naito
COO, Representative Executive Officer & Head-China:
Yasushi Okada
Chief Financial Officer & Chief IR Officer:
Tatsuyuki Yasuno
Chief Medical & Chief Clinical Officer-Neurology:
Lynn D. Kramer
Executive Officer & Head-Global IT Headquarters:
Keisuke Naito Shareholders
Wellington Management Co. LLP (8.0%)
Nomura Asset Management Co., Ltd. (6.0%)
Government of Japan (5.0%)
Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.3%)
Nippon Life Insurance Co. (3.2%)
Eisai Co., Ltd. (3.2%)
Asset Management One Co., Ltd. (3.0%)
Nikko Asset Management Co., Ltd. (2.9%)
Daiwa Asset Management Co. Ltd. (2.8%)
The Vanguard Group, Inc. (2.2%)
Contact Details Website: http://www.eisai.co.jp Address:
4-6-10 Koishikawa,
Bunkyo-Ku,
Tokyo,
112-8088,
Japan
Phone:
+81.3.3817.3700
Related Companies
Eisai Innovation, Inc.
Eisai Europe Ltd.
Eisai LLC
Eisai Machinery China Co. Ltd.
Eisai Laboratorios S de RL de CV
Eisai GesmbH
Eisai Farmaceutica, Unipessoal Lda.
Eisai Clinical Research Singapore Pte Ltd.
Eisai Ltd. (Canada)
Eisai SA/NV
Eisai (Malaysia) Sdn. Bhd.
Eisai (Thailand) Marketing Co., Ltd.
Eisai AB
Eisai Pharma AG
Eisai (Singapore) Pte Ltd.
Eisai Co. Ltd. /Misato Factory/
Eisai Board Incentive Plan
Eisai Corporate Pension Fund
Eisai Pension Fund
Eisai China, Inc.
H3 Biomedicine, Inc.
Eisai R&D Management Co., Ltd.
Herusu Co., Ltd.
Gakuen Shoji Co., Ltd.
PT Eisai Indonesia
Eisai Taiwan, Inc.
Eisai (Hong Kong) Co., Ltd.
Eisai Australia Pty Ltd.
Eisai Pharmaceuticals India Pvt Ltd.
Eisai GmbH
Competitors
JW Holdings Corporation
Ipsen SA
Ventyx Biosciences, Inc.
Denali Therapeutics Inc.
Immutep Ltd
JW Pharmaceutical Corporation
Morphic Holding, Inc.
Mirati Therapeutics Inc.
Exelixis, Inc.
Codiak BioSciences, Inc.
Blueprint Medicines Corp.
Arcutis Biotherapeutics Inc
Prometheus Biosciences, Inc
Aprea Therapeutics, Inc.
Verastem, Inc.
Cortexyme, Inc.
Ikena Oncology, Inc.
Iovance Biotherapeutics Inc
TCR2 Therapeutics, Inc.
Tyra Bioscience, Inc
Aeolus Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc.
AC Immune SA
Vivoryon Therapeutics N.V.
Xenon Pharmaceuticals Inc.
Prothena Corp. Plc
Vaxxinity Inc Class A
Aptinyx Inc
NeuroBo Pharmaceuticals, Inc.
Cyclerion Therapeutics,Inc.
Copyright © 2022 FactSet Research Systems Inc. All rights reserved.
Last Updated on 5 Jul, 2022
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter
Free access for everyone - Sep. 30
Find out more
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
Cookie Policy
to learn how you can update your cookie settings.
Accept & Continue
Close